Renalytix AI has successfully secured an extension for its listing on the Nasdaq exchange. This extension will allow the company to continue trading on the prestigious market. Renalytix AI is a leader in using artificial intelligence to improve kidney disease management. This development is a positive sign for the company and its investors.
Subscribe
Login
0 Comments